Sotatercept reduces bone morphogenetic protein signaling in patients with pulmonary arterial hypertension - PubMed

an hour ago

Pulmonary arterial hypertension (PAH) is linked to imbalances in TGF-β and BMPR-II pathways, with sotatercept studied as a potential therapeutic.
The StratosPHere 1 study explored BMP pathway biomarkers in peripheral blood, finding measurable and altered signaling in whole blood across cohorts.
A transcriptomic biomarker panel was developed, showing repeatability and stability, useful for early-phase clinical trials assessing target engagement.
In a pilot study with nine sotatercept-treated PAH patients, sotatercept reduced BMP pathway signaling, possibly due to depletion of BMP9 and BMP10.

Hasty Briefsbeta